1. Introduction {#s0005}
===============

In contrast to most other organs, the classification of surface epithelial tumours of the ovary (including serous and mucinous tumours) does not only include benign and malignant tumours, but also an intermediate category of so-called borderline tumours. From a pathological and etiological point of view, serous and mucinous borderline tumours are completely different, resulting in major differences in their biological behaviour ([@bb0100]). From a clinical point of view, intraoperative decision making is mainly dependent on the pathologists\' judgment regarding the frozen section analysis: benign, borderline, or malignant, considering the histological appearance of the tumour as less important at that timepoint. For this reason, some gynaecologists pragmatically group mucinous and serous borderline tumours together. Since the biological behaviour of borderline ovarian tumours is difficult to predict, optimal intraoperative management, with respect to frozen section analysis, followed by abdominal staging, remains a matter of debate.

According to Dutch guidelines, a surgical staging procedure is recommended when a Borderline Ovarian Tumour (BOT) is diagnosed during an exploratory laparotomy with frozen section analysis ([@bb0205]). Such a staging procedure includes, in addition to taking abdominal (rinsing) fluid for cytology and resection of at least the pathological adnex, a thorough inspection and palpation of the abdominal cavity, intestines and mesentery, omentum, and assessment of the contralateral ovary. Evident deviant areas must be excised. An infracolic omentectomy and collection of standardized peritoneal biopsies (from both paracolic gutters, the right diaphragmatic dome, the bladder dome and pouch of Douglas) is considered useful for finding peritoneal implants and determining the definite stage and related prognosis, but has no consequences for the treatment ([@bb0115]; [@bb0180]; [@bb0005]; [@bb0050]). Furthermore, an appendectomy is advised in case of a mucinous BOT (mBOT) ([@bb0075]; [@bb0165]). When a BOT diagnosis is established postoperatively, a relaparotomy is not indicated ([@bb0060]; [@bb0030]). Follow-up in case of BOTs is advised only for patients with a remaining ovary and patients with a serous BOT (sBOT) with invasive peritoneal implants, which are also designated as extra-ovarian low-grade serous carcinoma (LGSC) ([@bb0100]; [@bb0210]; [@bb0120]).

There are differences in clinical practice regarding perioperative treatment and follow-up of BOT patients amongst gynaecologic oncologists. Besides some optional parts of the staging procedure, another important difference in the treatment of BOTs amongst gynaecologic oncologists may be related to a discordance between the BOT frozen section diagnosis and a definite histopathological diagnosis of invasive ovarian cancer (10--17% of the patients) ([@bb0140]; [@bb0020]; [@bb0015]). Some gynaecologists advocate a staging procedure as is recommended in case of invasive ovarian carcinoma, with the risk of overtreatment, whereas others will await the definitive pathological diagnosis, which may necessitate a second surgical procedure to complete the staging procedure. Finally, the perioperative histopathological BOT diagnoses based on frozen section analyses may be not unambiguous (e.g., "borderline tumour of the ovary, but cannot exclude invasive cancer", "minimum borderline tumour of the ovary" or "borderline ovarian tumour and strong suspicion of invasive disease"), which is partly due to the common and well-known problem of sampling error in BOTs. It is interesting to know whether a gynaecologic oncologist will perform a second procedure in cases of invasive cancer as the final pathological result to complete staging irrespective of histological subtype. Recently, it has been shown that the chance of positive lymph nodes in case of mucinous ovarian carcinomas is rare, making it questionable whether lymph node staging is really necessary ([@bb0085]; [@bb0125]; [@bb0130]).

The aforementioned aspects may lead to different treatment and follow-up policies, which may ultimately lead to overtreatment because of unnecessary lymph node sampling and temporary undertreatment because of lack of lymph node sampling, necessitating a second procedure. To improve this, it is important to have more detailed information about current clinical practice regarding treatment and follow-up strategies of gynaecologic oncologists dealing with BOTs. The aim of the present study was to map the gynaecologists\' preferred treatment and follow-up strategy in The Netherlands, with a special interest in the preferred staging procedure in case of both ambiguous and unambiguous BOT frozen section diagnoses, how they deal with patients with a definitive diagnosis of invasive carcinoma and initial staging according to the BOT frozen section diagnosis and whether there are differences between serous and mucinous tumours regarding these situations.

2. Methods {#s0010}
==========

An anonymous electronic web-based questionnaire was developed according to the Checklist for Reporting Results of Internet *E*-Surveys (CHERRIES) guidelines (see [supplementary material 1](#ec0005){ref-type="supplementary-material"} for a completed checklist) ([@bb0055]). Approval of the Ethics Review Committee was unnecessary because all items of the questionnaire were based on fictitious cases and because this was a study amongst physicians.

The questionnaire was intended for gynaecologists who perform debulking surgery and/or staging procedures with respect to ovarian tumours. Dutch hospitals are classified according to their level of specialization as general, semi-specialized, or specialized hospitals (including all University hospitals). Since 2012, surgical care for ovarian cancer is centralized in the Netherlands, and staging and debulking surgery is solely executed in hospitals that perform a minimum of 20 debulking surgeries annually. These are semi-specialized or specialized hospitals, and the distinction between the two types of hospitals is defined by the employment of gynaecological oncologists. Following a two-year fellowship in gynaecologic oncology, the Dutch Society of Gynaecologic Oncology can certify members as gynaecological oncologists. In semi-specialized hospitals, gynaecological oncologists participate in each debulking surgery together with semi-specialized gynaecologists. In order to reach out to gynaecologists who perform staging procedures, the questionnaire was sent by email to all gynaecologists who are a member of the Working Party on Oncologic Gynaecology, which is part of the Dutch Association of Obstetrics and Gynaecology (<http://www.nvog.nl>) (*n* = 251).

Of these 251 gynaecologists, 59 are a gynaecologic oncologist and 10 are gynaecologic oncologist in training. The remainder are semi-specialized or general gynaecologists, the latter being gynaecologists with an interest in gynaecological oncology, but who do not fit in any of the foregoing professional profiles.

All authors were involved in compiling and testing the questionnaire, which consisted of a maximum of 27 items (see [supplementary material 2](#ec0010){ref-type="supplementary-material"}) concerning staging procedures in case of BOTs. It was taken into account that a considerable number of possible respondents do not perform ovarian surgery with frozen section analysis, but might have done so in the past. In those cases, the questionnaire was completed after the 4th question. The first part consisted of general questions (e.g., the gynaecologist\'s gender, professional function), the second and third part were aimed at the surgical strategy in case of sBOTs or mBOTs, respectively. The last two parts of the survey involved questions with respect to the follow-up of sBOTs and mBOTs, respectively. All questions were multiple choice, and it was possible to specify the answer for some questions.

Invitation emails with a personal link to start the survey were sent in July of 2017. Reminders were sent after 4 and 8 weeks (only to gynaecologists who had not responded) and the system was closed after 12 weeks. Once the questionnaire was completed, it was closed and could not be accessed again. All answers were stored in the survey system automatically, and after exporting, the data were analysed with SPSS (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.).

3. Results {#s0015}
==========

The survey was started by 48 gynaecologists and completed by 45. Only the completed questionnaires were included. Of these 45 responders, 22 were a gynaecologic oncologist (48.9%), 22 were a semi-specialized or general gynaecologist (48.9%) and one was a fellow in gynaecologic oncology (2.2%). So, over one third (37.7.3%) of the gynaecologic oncologists responded to the questionnaire. [Table 1](#t0005){ref-type="table"} shows the respondents\' baseline characteristics. Six respondents did not perform surgical procedures (anymore). Their questionnaire was completed after the fourth question (because further questions were not applicable to them), and only the remaining respondents (*n* = 39) were included in further analyses.Table 1Respondents\' baseline characteristics.Table 1What is your gender?n (%)•Male24 (53.3)•Female21 (46.7)**How long are you working as a gynaecologist?Mean** **±** **SD**•Overall16.2 ± 8.8•Male19.9 ± 8.8•Female12.1 ± 6.9**What is your professional function?n (%)**•Gynaecologist with semi-specialization in gynaecologic oncology.22 (48.9)•Gynaecologic oncologist.22 (48.9)•Fellow gynaecologic oncology.1 (2.2)**How many hours do you spend on gynaecologic oncologic surgery, including surgery with frozen section analysis, each week?n (%)**•I do not participate in surgical procedures anymore, or it only concerns surgical procedures other than ovarian surgery (with frozen section analysis).6 (13.3)•0--513 (28.9)•5--1013 (28.9)•10--159 (20.0)•15--203 (6.7)•≥201 (2.2)**How many patients do you diagnose with a BOT each year (n** **=** **39)?n (%)**•0--512 (30.8)•5--1019 (48.7)•10--155 (12.8)•15--202 (5.1)•≥201 (2.6)

In cases of unambiguous sBOT and mBOT frozen section diagnoses, about half of the respondents (*n* = 16, 41.0%) would not collect abdominal (rinsing) fluid for cytology, neither perform an infracolic omentectomy or omental biopsy, nor collect multiple peritoneal biopsies (no staging procedure). Two gynaecologists (5.1%) would only collect abdominal (rinsing) fluid for cytology with respect to both histological types, and one collects abdominal (rinsing) fluid for cytology and collects a biopsy of the omentum in case of an unambiguous sBOT frozen section diagnosis. In case of mBOTs, an appendectomy was considered a standard procedure within the staging procedure by two thirds of the respondents, and the remaining respondents would only remove the appendix when the macroscopic appearance is abnormal.

In case of ambiguous sBOT frozen section diagnoses, the number of respondents who would perform a staging procedure substantially increased (from 51.3% to 87.2%), and the majority (56.4%) also would include a lymph node sampling as part of the staging procedure. In addition, in case of an ambiguous mBOT frozen section diagnosis the majority of respondents would perform a staging procedure (87.2%), but a minority (30.8%) would a include lymph node sampling as part of the staging procedure (see [Table 2](#t0010){ref-type="table"}). A relaparotomy or relaparoscopy to complete the staging procedure with a lymph node sampling, in case of a definite diagnosis of an assumed FIGO stage I invasive carcinoma (e.g., discordant frozen section diagnosis), would be performed by all but one respondent in case of a serous tumour (97.4%) and by almost half of the respondents in case of a mucinous tumour (48.7%). With respect to lymph node sampling in case of both serous and mucinous tumours, the majority of respondents would perform a bilateral pelvic and high para-aortic/paracaval lymph node sampling and prefers removal of at least 10 lymph nodes (see [Table 3](#t0015){ref-type="table"}).Table 2Extent of the staging procedures performed by the respondents with respect to unambiguous and ambiguous frozen section diagnoses in case of a serous or mucinous ovarian tumour (n = 39).Table 2Serous tumourMucinous tumourUnambiguous BOT frozen section diagnosisAmbiguous BOT frozen section diagnosisUnambiguous BOT frozen section diagnosisAmbiguous BOT frozen section diagnosis**What kind of staging procedure do you perform during an exploratory laparotomy in case of an ovarian tumour, when no further abnormalities are seen during inspection of the abdominal cavity?n (%)n (%)n (%)n (%)**•No staging procedure.16 (41.0)5 (12.8)16 (41.0)5 (12.8)•Infracolic omentectomy (or collection omental biopsies) and collection of ascitic fluid and peritoneal biopsies (standard BOT staging procedure).20 (51.3)12 (30.8)21 (53.8)22 (56.4)•Ovarian carcinoma staging procedure (infracolic omentectomy, peritoneal biopsies, lymph node sampling).0 (0.0)22 (56.4)0 (0.0)12 (30.8)•Otherwise, ...3 (7.7%)0 (0.0)2 (5.1)0 (0.0)Table 3Anatomical sites of lymph node sampling and the preferred number of removed lymph nodes in case of a serous or mucinous ovarian tumour with a questionable perioperative BOT frozen section diagnosis or in case of a relaparatomy or relaparoscopy after diagnosis of invasive carcinoma with a standard BOT staging procedure during initial surgery.Table 3Serous tumourMucinous tumourQuestionable BOT frozen section diagnosis (*n* = 22)Second surgery after diagnosis of invasive carcinoma (*n* = 38)Questionable BOT frozen section diagnosis (n = 12)Second surgery after diagnosis of invasive carcinoma (*n* = 19)**At which locations do you perform the lymph node sampling?n (%)n (%)n (%)n (%)**•Ipsilateral in the pelvic region.0 (0.0)0 (0.0)1 (8.3)0 (0.0)•Bilateral in the pelvic region.1 (4.5)1 (2.6)1 (8.3)2 (10.5)•Ipsilateral in the pelvic region and high para-aortic/paracaval.3 (13.6)5 (13.2)2 (16.7)1 (5.3)•Bilateral in the pelvic region and high para-aortic/paracaval.18 (81.8)32 (84.2)8 (66.7)16 (84.2)•Only high para-aortic/paracaval.0 (0.0)0 (0.0)0 (0.0)0 (0.0)**What is the preferred number of removed lymph nodes?n (%)n (%)n (%)n (%)**•No minimum number.4 (18.2)4 (10.5)2 (16.7)2 (10.5)•1016 (72.7)28 (73.7)9 (75.0)16 (84.2)•202 (9.1)6 (15.8)1 (8.3)1 (5.3)

Follow-up visitations of patients with a FIGO stage I BOT are considered unnecessary by more than half of the respondents with respect to both serous and mucinous tumours. Some gynaecologists would only offer follow-up according to patient preference, and a small number would offer follow-up at their own initiative (see [Table 4](#t0020){ref-type="table"}). With respect to extra-ovarian disease, all gynaecologists offer follow-up visitations in case of invasive implants/extra-ovarian LGCS and almost half of them would already offer follow-up in case of non-invasive implants. Regarding follow-up of FIGO stage I sBOTs (*n* = 14), almost half of the respondents would offer follow-up visitations according to a schedule that is common in case of epithelial ovarian carcinoma. The remaining respondents apply a different follow-up scheme, for instance follow-up visitations every six months (*n* = 5) or yearly (*n* = 2), where some indicate that this usually is not as long as is common for ovarian carcinoma (e.g., 2 years). The applied follow-up schedules in case of mBOTs (*n* = 12) are comparable to those in case of sBOTs (see [Table 4](#t0020){ref-type="table"}). The majority of respondents consider anamnesis, transvaginal/−abdominal ultrasound and gynaecologic examination (vaginal examination with or without speculum) as standard procedures during follow-up visitations of patients with a BOT. Approximately half of the respondents routinely checks serum Ca-125 levels.Table 4Respondents\' follow-up strategies in case of BOTs.Table 4SerousMucinous**Follow-up of a FIGO stage I BOT is considered unnecessary by the Dutch guideline. Do you agree (n** **=** **39)?n (%)n (%)**•Yes, I will not offer follow-up visitations (except one postoperative check).25 (64.1)27 (69.2)•Yes, I will not offer follow-up unless the patients prefers this.9 (23.1)8 (20.5)•No, I will offer follow-up on my own initiative.5 (12.8)4 (10.3)**Which follow-up schedule would you apply in case you would offer follow-up in patients with a FIGO stage I sBOT (n** **=** **14) or mBOT (n** **=** **12)?n (%)n (%)**•A follow-up schedule as is common for epithelial ovarian carcinoma.6 (42.9)4 (33.3)•Otherwise, ...8 (57.1)8 (66.7)**In case you would not offer follow-up visitation in case of a FIGO stage I BOT, would you do this in case of extra-ovarian disease in the omentum or other peritoneal surfaces (n** **=** **39)?n (%)n (%)**•Not applicable, I would offer follow-up visitations anyway.4 (10.3)Not applicable•Yes, in that case I would offer follow-up visitations.17 (43.6)•Yes, but only but only if it concerns invasive implants.18 (46.2)•No, I would still not offer follow-up visitations.0 (0)**During a follow-up visitation of an sBOT (n** **=** **14) or mBOT (n** **=** **12) I consider the following procedures as standard:n (%)n (%)**•Anamnesis14 (100)12 (100)•Transvaginal/−abdominal ultrasound13 (92.9)11 (91.7)•Gynaecologic examination (vaginal examination with or without speculum)10 (71.4)9 (75)•Serum Ca-125 levels8 (57.1)5 (41.7)•Additional imaging studies1 (7.1)0 (0)•Cytological examination of the vaginal vault0 (0)0 (0)

4. Discussion {#s0020}
=============

In daily practice, several factors, such as the limited consequences of staging procedures in BOTs, differences in clinicopathological behaviour between the histological types, the possibility of discordance between frozen section and definite diagnosis and an ambiguous perioperative frozen section diagnosis may lead to differences between gynaecologists\' treatment and follow-up strategies, which may ultimately lead to over- and undertreatment. To be able to minimize this possible over- and undertreatment, it was considered useful to gain more knowledge about current practice and opinions regarding treatment and follow-up strategies pertaining to BOTs. The current questionnaire-based study is the first to provide insight into the Dutch gynaecologists\' surgical strategy related to BOTs based on frozen section diagnoses. Furthermore, the questionnaire mapped whether the respondents offer follow-up visits to their patients and if so, what diagnostic tools are used to screen for a recurrence.

In case of a straightforward sBOT and mBOT frozen section diagnosis, approximately half of the respondents would perform a staging procedure, which is significantly less than the 97% reported by [@bb0105]. This may be explained by the fact that later research has shown that upstaging may predict a worse prognosis, but does not have any influence on further treatment strategies and survival rates ([@bb0115]; [@bb0180]; [@bb0060]; [@bb0030]; [@bb0105]; [@bb0095]; [@bb0195]; [@bb0200]). When the results of frozen section analyses are not straightforward and might tend towards the diagnosis of serous invasive carcinoma, the number of respondents that would perform a complete staging procedure substantially increased, and more than half of the respondents would even perform a staging procedure as recommended in case of invasive ovarian carcinoma, which includes a lymph node sampling. Apparently, those respondents assume that the risk for an invasive carcinoma and the subsequent need for a second procedure (no lymph node sampling during initial surgery) outweighs the chance for overtreatment (unnecessary lymph node sampling during the first procedure) in cases where BOT is the definite diagnosis. A contributing factor to this strategy may be the aforementioned probability of discordance between the frozen section analysis (BOT) and definite diagnosis (invasive carcinoma) in 10--17% of the patients ([@bb0140]; [@bb0020]; [@bb0015]). In addition, in case of an ambiguous frozen section diagnosis, tending towards the diagnosis of mucinous invasive carcinoma, the number of respondents that would perform a complete BOT staging procedure substantially increases. However, in contrast to serous tumours, only a minority would include a lymph node sampling as part of the staging procedure (30.8% versus 56.4%). The same is true for the number of respondents that would perform a relaparotomy or laparoscopy to complete the surgical staging with a lymph node sampling in case of patients in whom a BOT frozen section result was changed to an invasive carcinoma (48.7% and 97.4% in mucinous and serous tumours, respectively). The more aggressive strategy in case of serous ovarian tumours is most likely because of the fact that serous ovarian carcinomas have a significantly higher chance of occult lymph node metastases and because adjuvant chemotherapy is more beneficial when compared to mucinous ovarian carcinomas ([@bb0085]; [@bb0010]; [@bb0160]; [@bb0145]; [@bb0150]; [@bb0155]).

Despite the fact that bilateral pelvic, and high para-aortic/paracaval lymph node sampling is recommended, some respondents (+/− 20%) indicated that they would perform a less extensive sampling \[only (ipsilateral) pelvic lymph node sampling or ipsilateral pelvic with high para-aortic/paracaval sampling\], without major differences with respect to both histological subtypes ([@bb0135]; [@bb0040]; [@bb0190]). Concerning the minimum number of removed lymph nodes, the majority of respondents prefer removal of at least 10 lymph nodes, which is also recommended by the Dutch guideline and some previous reports ([@bb0045]; [@bb0035]). However, some of the respondents advocate removal of at least 20 lymph nodes, probably because the 5-year survival rate seems to improve in those cases ([@bb0090]).

With regard to follow-up of BOTs in case of a bilateral salpingo-oophorectomy (BSO), approximately two thirds of the respondents report that follow-up visits in those cases (without extra-ovarian disease) are irrational because of the high disease free and overall survival rates of BOTs ([@bb0175]; [@bb0080]). In contrast, all of the respondents offer follow-up visits in case of invasive extra-ovarian disease. However, the respondents offering follow-up apply different schedules with respect to the frequency and duration of follow-up. Some respondents advocate applying ovarian cancer post-treatment surveillance guidelines to patients with BOTs (with or without extra-ovarian disease), which is not in agreement with the Dutch guideline but which is recommended by others ([@bb0185]; [@bb0025]; [@bb0215]). With respect to the procedures performed during follow-up visits regarding BOTs after a BSO, the majority of respondents would perform a clinical examination and vaginal ultrasound examination ([@bb0220]; [@bb0170]; [@bb0065]). Furthermore, approximately half of the respondents determines serum Ca-125 levels, which is recommended by some authors. However, serum Ca-125 are less often elevated in case of sBOTs, when compared to serous carcinomas, and they are rarely elevated in mBOTs ([@bb0025]; [@bb0220]; [@bb0070]; [@bb0110]).

Our study has several limitations. First of all, the questionnaire was designed and tested only by the author panel. There was no validation of the survey by a pilot study because of the small size of the target population, which made it impossible to adjust and improve the content of the questionnaire after initial testing. However, it is questionable whether these limitations affected the outcomes. Another limitation of this study was the moderate response rate. To reach out to gynaecologists involved in ovarian surgery with perioperative frozen section analysis, the questionnaire was sent to a large group of potential respondents (all gynaecologist members of the Dutch Working Party on Oncologic Gynaecology). It is known that invitations to such questionnaires are frequently declined because of a lack of time, interest or knowledge. Nevertheless, over one third of the gynaecologic oncologists who should perform or supervise all ovarian surgery with frozen section analysis completed the survey, which is sufficient to gain insight into the current daily practice with respect to BOTs. On the other hand, gynaecologic oncologists, who are involved in all procedures, might have biased the answers of the remaining respondents (semi-specialized gynaecologists or fellow gynaecologic oncology).

In conclusion, it can be stated that different treatment strategies are applied by the Dutch gynaecologists involved in ovarian surgery with perioperative frozen section analysis. It should be noted that approximately half of the gynaecologists do not perform a staging procedure in case of BOTs, while the number decreases in case of an ambiguous frozen section result. Furthermore, a considerable number of gynaecologists would perform a staging procedure including a lymph node sampling in case of an ambiguous BOT frozen section diagnosis, especially in case of serous tumours. In addition, nearly all gynaecologists would perform a relaparotomy or laparoscopy to perform a lymph node sampling in case of a presumed FIGO stage I serous invasive carcinoma after a BOT frozen section diagnosis, which applies to only half of the gynaecologists in case of a mucinous carcinoma. Lymph node sampling is performed in the recommended regions by the majority of gynaecologists, but some prefer a less extensive sampling, which is also true for the minimum number of removed lymph nodes. Last but not least, the follow-up strategy varies considerably amongst gynaecologists, especially with respect to the duration and frequency of follow-up and also with regard to what diagnostic tools are used. Future studies should focus on whether the aforementioned differences with respect to treatment and follow-up policies regarding BOTs have any consequences for patient outcomes.
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